Immunovant Reports Positive Initial Phase 1 SAD and 300 mg Subcutaneous MAD Results for IMVT-1402

(24/7 MARKET NEWS) – Immunovant, Inc. (NASDAQ:IMVT) reported, this morning, that subcutaneously administered doses of IMVT-1402 achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, in initial data from a Phase 1 clinical trial in healthy adults, with no decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohort.

Immunovant trading at $29.02, up $8.28 (+43.09%), on 726.6K premarket shares traded.

Its 52-week range is $4.495 to $25.1284. It gapped through its 52-week high.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist